Cytokinetics (CYTK) PT Lowered to $80 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $62.10 -0.34%
Rating Summary:
24 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Rating Summary:
24 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Join SI Premium – FREE
RBC Capital analyst Leonid Timashev lowered the price target on Cytokinetics (NASDAQ: CYTK) to $80.00 (from $82.00) while maintaining a Outperform rating.
You May Also Be Interested In
- AMD (AMD) PT Raised to $600 at DA Davidson
- TETRA Technologies Inc. (TTI) PT Lowered to $11 at Stifel
- Viridian Therapeutic (VRDN) PT Raised to $43 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
